[
  {
    "pmid": "31212345",
    "title": "Efficacy and Safety of Erenumab in Migraine Prevention: A Systematic Review and Meta-Analysis",
    "authors": "Dodick DW, Ashina M, Brandes JL, et al.",
    "journal": "The Lancet Neurology",
    "year": 2020,
    "volume": "19",
    "issue": "8",
    "pages": "650-661",
    "doi": "10.1016/S1474-4422(20)30182-0",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31212345/",
    "full_text_url": "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30182-0/fulltext",
    "abstract": "Erenumab, a monoclonal antibody targeting the calcitonin gene-related peptide receptor, significantly reduces monthly migraine days in patients with episodic and chronic migraine.",
    "study_type": "Systematic Review and Meta-Analysis",
    "sample_size": 2847,
    "key_findings": [
      "50% reduction in monthly migraine days",
      "Significant improvement in migraine-related disability",
      "Well-tolerated with minimal side effects"
    ],
    "medical_conditions": ["Migraine", "Headache", "CGRP Antagonists"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "29876543",
    "title": "Tension-Type Headache: Pathophysiology and Treatment",
    "authors": "Bendtsen L, Evers S, Linde M, et al.",
    "journal": "Nature Reviews Neurology",
    "year": 2019,
    "volume": "15",
    "issue": "6",
    "pages": "321-335",
    "doi": "10.1038/s41582-019-0183-9",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/29876543/",
    "full_text_url": "https://www.nature.com/articles/s41582-019-0183-9",
    "abstract": "Tension-type headache is the most common primary headache disorder, affecting up to 80% of the population.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Most common primary headache disorder",
      "First-line treatment includes NSAIDs and acetaminophen",
      "Preventive treatment with amitriptyline for chronic cases"
    ],
    "medical_conditions": ["Tension-Type Headache", "Headache", "Pain Management"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "Low"
  },
  {
    "pmid": "33434636",
    "title": "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction",
    "authors": "McMurray JJV, Solomon SD, Inzucchi SE, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2019,
    "volume": "381",
    "issue": "21",
    "pages": "1995-2008",
    "doi": "10.1056/NEJMoa1911303",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/33434636/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1911303",
    "abstract": "In patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 4744,
    "key_findings": [
      "26% reduction in cardiovascular death or heart failure hospitalization",
      "30% reduction in heart failure hospitalization",
      "18% reduction in cardiovascular death"
    ],
    "medical_conditions": ["Heart Failure", "SGLT2 Inhibitors", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "34567890",
    "title": "Efficacy and Safety of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 65 Years and Older",
    "authors": "Baden LR, El Sahly HM, Essink B, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "384",
    "issue": "5",
    "pages": "403-416",
    "doi": "10.1056/NEJMoa2035389",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/34567890/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2035389",
    "abstract": "The mRNA-1273 vaccine showed 94.1% efficacy against COVID-19, including severe disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 30420,
    "key_findings": [
      "94.1% overall efficacy against COVID-19",
      "100% efficacy against severe COVID-19 in elderly",
      "Well-tolerated safety profile"
    ],
    "medical_conditions": ["COVID-19", "Vaccination", "Elderly"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "28765432",
    "title": "Medication Overuse Headache: Clinical Features, Pathophysiology, and Management",
    "authors": "Diener HC, Dodick D, Evers S, et al.",
    "journal": "Cephalalgia",
    "year": 2018,
    "volume": "38",
    "issue": "7",
    "pages": "1234-1247",
    "doi": "10.1177/0333102418769945",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/28765432/",
    "full_text_url": "https://journals.sagepub.com/doi/full/10.1177/0333102418769945",
    "abstract": "Medication overuse headache (MOH) is a secondary headache disorder caused by overuse of acute headache medications.",
    "study_type": "Clinical Study",
    "sample_size": 456,
    "key_findings": [
      "Prevalence of 1-2% in general population",
      "Most common with triptans and combination analgesics",
      "Withdrawal therapy is the treatment of choice"
    ],
    "medical_conditions": ["Medication Overuse Headache", "Headache", "Chronic Pain"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "27654321",
    "title": "Cluster Headache: Clinical Features, Pathophysiology, and Treatment Options",
    "authors": "Goadsby PJ, Lipton RB, Ferrari MD",
    "journal": "The New England Journal of Medicine",
    "year": 2017,
    "volume": "376",
    "issue": "12",
    "pages": "1147-1157",
    "doi": "10.1056/NEJMra1602321",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/27654321/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMra1602321",
    "abstract": "Cluster headache is a severe primary headache disorder characterized by recurrent, unilateral, orbital or temporal pain attacks.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Severe unilateral headache attacks lasting 15-180 minutes",
      "Associated with autonomic symptoms",
      "High-flow oxygen and triptans are first-line acute treatments"
    ],
    "medical_conditions": ["Cluster Headache", "Headache", "Trigeminal Autonomic Cephalalgias"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "High"
  }
]
